Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
Travere Therapeutics has entered an exclusive licensing agreement with Everest Medicines for civorebrutinib, a next-generation oral BTK inhibitor. Travere will pay an upfront fee of $112.5 million and is eligible for up to $1.03 billion in milestones across five indications, plus tiered royalties on sales.
Key figures
- Deal Value Usd
- 112500000
- Milestone count
- up to 5 indications
- Upfront payment
- $112.5 million
- Potential milestones
- $1.03 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.